TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2544254

Group type: EXPERIMENTAL
Intervention: Central parenteral nutrition (CPN)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Peripheral parenteral nutrition (PPN) plus enteral nutrition (EN)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Enteral nutrition (EN)
Number of subjects: 31
Study: 31659803

Group type: EXPERIMENTAL
Intervention: GB001 (30 mg) once daily for 28 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 29868915

Group type: EXPERIMENTAL
Intervention: 25 mg of pure (‐)‐epicatechin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 26569451

Group type: EXPERIMENTAL
Intervention: Light intensity treadmill walking exercise
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Moderate intensity treadmill walking exercise
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Vigorous intensity treadmill walking exercise
Number of subjects: 24

Group type: COMPARATOR
Intervention: Quiet rest
Number of subjects: 24
Study: 24056269

Group type: EXPERIMENTAL
Intervention: Aquatic treadmill training (ATM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Land-based treadmill training (LTM)
Number of subjects: 60
Study: 21944980

Group type: EXPERIMENTAL
Intervention: End-range mobilization/scapular mobilization treatment approach (EMSMTA)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standardized physical therapy program (criteria-control group)
Number of subjects: 34
Study: 20739447

Group type: EXPERIMENTAL
Intervention: Multivitamins (B complex, C, and E)
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Vitamin A + β‐carotene
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Multivitamins (B complex, C, and E) among women with CD4+ T-cell counts ≥ 350 cells/μL
Number of subjects: 674

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 674
Study: 18288087

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 0
Study: 15820454

Group type: EXPERIMENTAL
Intervention: Oral linezolid
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous vancomycin
Number of subjects: 60
Study: 12595859

Group type: EXPERIMENTAL
Intervention: Premounted stents
Number of subjects: 123

Group type: COMPARATOR
Intervention: Unmounted stents
Number of subjects: 123
Study: 10594478

Group type: EXPERIMENTAL
Intervention: Dipyridamole (200 mg) plus Acetylsalicylic Acid (25 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo or Acetylsalicylic Acid (ASA) alone
Number of subjects: 0
Study: 1978472

Group type: EXPERIMENTAL
Intervention: Remoxipride (mean daily dose 437 mg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Haloperidol (mean daily dose 10.6 mg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Haloperidol (control)
Number of subjects: 96
Study: 104084

Group type: EXPERIMENTAL
Intervention: Trifluorothymidine (5 drops daily)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 56
Study: 31915048

Group type: EXPERIMENTAL
Intervention: 1 week of antibiotic therapy for residual osteomyelitis
Number of subjects: 400

Group type: COMPARATOR
Intervention: 3 weeks of antibiotic therapy for residual osteomyelitis
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 1 day of antibiotic therapy for remaining soft tissue infection
Number of subjects: 400

Group type: COMPARATOR
Intervention: 4 days of antibiotic therapy for remaining soft tissue infection
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 10 days of antibiotic therapy for soft tissue infections
Number of subjects: 400

Group type: COMPARATOR
Intervention: 20 days of antibiotic therapy for soft tissue infections
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 3 weeks of antibiotic therapy for osteomyelitis
Number of subjects: 400

Group type: COMPARATOR
Intervention: 6 weeks of antibiotic therapy for osteomyelitis
Number of subjects: 400
Study: 30707056

Group type: EXPERIMENTAL
Intervention: ASCO-NHB v2
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Thresholds for ASCO-NHB v2
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: ESMO-MCBS v1.1
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Discordant studies
Number of subjects: 102
Study: 27693478

Group type: EXPERIMENTAL
Intervention: Dismembered pyeloplasty without external nephro-ureteric stent (group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dismembered pyeloplasty with external nephro-ureteric stent (ENUS) (group B)
Number of subjects: 30
Study: 26048004

Group type: EXPERIMENTAL
Intervention: Aware condition (participants informed of UEM presence)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Unaware condition (participants not informed of UEM presence)
Number of subjects: 39
Study: 23379539

Group type: EXPERIMENTAL
Intervention: HA/β‐TCP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HA/β‐TCP-EMD
Number of subjects: 30
Study: 22204724

Group type: EXPERIMENTAL
Intervention: Bevacizumab initiation (chemotherapy with bevacizumab added in cycles 2 through 6 and placebo in cycles 7 through 22)
Number of subjects: 1873

Group type: EXPERIMENTAL
Intervention: Bevacizumab throughout (chemotherapy with bevacizumab added in cycles 2 through 22)
Number of subjects: 1873

Group type: COMPARATOR
Intervention: Control (chemotherapy with placebo added in cycles 2 through 22)
Number of subjects: 1873

Group type: COMPARATOR
Intervention: Control (chemotherapy with placebo)
Number of subjects: 1873

Group type: EXPERIMENTAL
Intervention: Bevacizumab initiation
Number of subjects: 1873

Group type: EXPERIMENTAL
Intervention: Bevacizumab throughout
Number of subjects: 1873

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1873
Study: 19367154

Group type: EXPERIMENTAL
Intervention: HSV suppressive therapy for 4-6 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HSV suppressive therapy
Number of subjects: 0
Study: 17323789

Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg single dose
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fingolimod 2.5 mg single dose
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fingolimod 5 mg single dose
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fingolimod 5 mg/day for 7 days
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fingolimod multiple-dose administration
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fingolimod single and multiple doses
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fingolimod 5 mg/day multiple dose
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fingolimod first dose
Number of subjects: 25
Study: 15247960

Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 44

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 44
Study: 12434778

Group type: EXPERIMENTAL
Intervention: OSHA Local Emphasis Program (LEP) for ergonomics; inspections initiated between 1992 and 1995.
Number of subjects: 14

Group type: COMPARATOR
Intervention: New Hampshire employers not receiving an inspection focused on upper extremity cumulative trauma hazards.
Number of subjects: 14
Study: 9845149

Group type: EXPERIMENTAL
Intervention: Septal position of the distal spring lead in the right ventricle
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-septal position of the distal spring lead in the right ventricle
Number of subjects: 20
Study: 7517171

Group type: EXPERIMENTAL
Intervention: FK-506
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: FK-506 (no prednisone)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 48
Study: 3198303

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atenolol plus nifedipine (10 mg t.i.d.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nifedipine (10 mg t.i.d.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 477047

Group type: EXPERIMENTAL
Intervention: 0.125 mg 3H‐digoxin intravenously and 0.125 mg orally as an alcoholic solution
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0.5 mg unlabelled digoxin intravenously or a digoxin tablet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both groups of patients
Number of subjects: 12
Study: 30717153

Group type: EXPERIMENTAL
Intervention: DW2009 (800 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (800 mg/day)
Number of subjects: 100
Study: 28195387

Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 5213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5213
Study: 25961136

Group type: EXPERIMENTAL
Intervention: Daily TPTD for 24 months
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cyclical TPTD (four 3-month cycles)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Daily TPTD for 24 months in ALN-Rx women
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cyclical TPTD (four 3-month cycles) in ALN-Rx women
Number of subjects: 150
Study: 23566363

Group type: EXPERIMENTAL
Intervention: Screening and Brief Intervention (SBI)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Attention-placebo control
Number of subjects: 700
Study: 22613418

Group type: EXPERIMENTAL
Intervention: Packed red blood cells (PRBCs) transfusion during liver transplantation (group LP)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Packed red blood cells (PRBCs) transfusion during spinal surgery (group SP)
Number of subjects: 52

Group type: COMPARATOR
Intervention: 0.9% normal saline infusion during spinal surgery (group SN)
Number of subjects: 52
Study: 19906909

Group type: EXPERIMENTAL
Intervention: 3.5 microg of the H5N1 vaccine (one or two doses)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: 6 microg of the H5N1 vaccine (single dose)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: 12 microg of the H5N1 vaccine (single dose)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: 3.5 microg of the H5N1 vaccine (one injection)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: 3.5 microg of the H5N1 vaccine
Number of subjects: 480
Study: 17914516

Group type: EXPERIMENTAL
Intervention: Topical mitomycin C (MMC) 0.4 mg/mL for 4 minutes
Number of subjects: 20

Group type: COMPARATOR
Intervention: No mitomycin C (non-MMC)
Number of subjects: 20
Study: 16275598

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 47

Group type: COMPARATOR
Intervention: All three drugs (Desipramine, Amitriptyline, Fluoxetine)
Number of subjects: 47
Study: 11861354

Group type: EXPERIMENTAL
Intervention: inhaled nitric oxide (iNO) 10 ppm in 100% oxygen
Number of subjects: 14
Study: 10453869

Group type: EXPERIMENTAL
Intervention: Heated humidity
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Cold passover humidity
Number of subjects: 38

Group type: COMPARATOR
Intervention: No humidity (washout period)
Number of subjects: 38
Study: 7888515

Group type: EXPERIMENTAL
Intervention: Isoflurane-based anaesthesia
Number of subjects: 150

Group type: COMPARATOR
Intervention: Propofol-based anaesthesia
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: First 8 days of the menstrual cycle (in isoflurane group)
Number of subjects: 150
Study: 2266675

Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 535856

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (specific types not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two oral contraceptives (different in dosage)
Number of subjects: 0
Study: 31939768

Group type: EXPERIMENTAL
Intervention: Higher trait-level intergroup anxiety
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trait-level intergroup anxiety and state-level comfort
Number of subjects: 0
Study: 30920716

Group type: EXPERIMENTAL
Intervention: Transpedal approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Femoral approach
Number of subjects: 0
Study: 28575534

Group type: EXPERIMENTAL
Intervention: Higher CCL2 levels
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Higher IL-10 levels
Number of subjects: 437

Group type: COMPARATOR
Intervention: Higher IL-6 levels
Number of subjects: 437
Study: 25366519

Group type: EXPERIMENTAL
Intervention: 6-month training intervention (N=16)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Usual care (N=11)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: pwMS (N=37)
Number of subjects: 37
Study: 23988507

Group type: EXPERIMENTAL
Intervention: High-dose-rate (HDR) brachytherapy (BT) boost after external beam irradiation (mean dose 62 Gy, range 50-70 Gy)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Radiochemotherapy (RCT) with cisplatin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tumor size (T1-T2-T3) vs. T4
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nodal status (N0 vs. N+)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Histologic grade (1-2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Radiochemotherapy (RCT)
Number of subjects: 60
Study: 21819160

Group type: EXPERIMENTAL
Intervention: saxagliptin/metformin XR 5 mg/500 mg FDC
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: saxagliptin/metformin XR 5 mg/1000 mg FDC
Number of subjects: 30

Group type: COMPARATOR
Intervention: saxagliptin 5 mg and metformin XR 500 mg co-administered
Number of subjects: 30
Study: 19376321

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 2130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2130
Study: 16340517

Group type: EXPERIMENTAL
Intervention: Free nicotine replacement therapy (NRT) voucher
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Better Quit® (BQ) cigarette substitute
Number of subjects: 732
Study: 15603005

Group type: EXPERIMENTAL
Intervention: Vocational Problem Solving
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Job Seekers Workshop
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined trainings
Number of subjects: 0
Study: 11403336

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 200 mg twice daily for 11 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 200 mg twice daily plus colchicine 0.6 mg twice daily for 12 weeks
Number of subjects: 20
Study: 9230829

Group type: EXPERIMENTAL
Intervention: Nonrandomized prospective follow-up study
Number of subjects: 204
Study: 8434515

Group type: EXPERIMENTAL
Intervention: Continuous irrigation-drainage system
Number of subjects: 37

Group type: COMPARATOR
Intervention: Evacuation via burr holes and gravity dependent closed-system drainage
Number of subjects: 37
Study: 3312552

Group type: EXPERIMENTAL
Intervention: Indomethacin (0.2 mg/kg intravenously, 24 hours after birth)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no indomethacin given until symptomatic PDA developed)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Indomethacin and Control
Number of subjects: 32
Study: 29405106

Group type: EXPERIMENTAL
Intervention: Community-led total sanitation (CLTS) intervention with training facilitators
Number of subjects: 171
Study: 27015752

Group type: EXPERIMENTAL
Intervention: Conventional fixation (open, direct reduction)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Biological fixation (indirect reduction)
Number of subjects: 46
Study: 24727254

Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 3627

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3627
Study: 23579888

Group type: EXPERIMENTAL
Intervention: hemostatic agent‐contaminated and rinsing with water
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: hemostatic agent‐contaminated and ethylene diamine tetraacetic acid (EDTA) application
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: hemostatic agent‐contaminated and phosphoric acid application
Number of subjects: 100

Group type: COMPARATOR
Intervention: control
Number of subjects: 100
Study: 20826420

Group type: EXPERIMENTAL
Intervention: Kinesiotaping combined with botulinum toxin A (BTX‐A) injection
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham-taping combined with botulinum toxin A (BTX‐A) injection
Number of subjects: 20
Study: 18565801

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 153

Group type: COMPARATOR
Intervention: Non-tailored counseling
Number of subjects: 153

Group type: COMPARATOR
Intervention: Tailored counseling
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Run-in period
Number of subjects: 153
Study: 16267427

Group type: EXPERIMENTAL
Intervention: Paper tape applied to scars for 12 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: No postoperative intervention (Control)
Number of subjects: 70
Study: 11919122

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10080458

Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 220

Group type: COMPARATOR
Intervention: Systemic thrombolysis with t-PA
Number of subjects: 220
Study: 7723357

Group type: EXPERIMENTAL
Intervention: Isomazole 5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isomazole 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isomazole 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isomazole 30 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isomazole (all doses)
Number of subjects: 12
Study: 2035280

Group type: EXPERIMENTAL
Intervention: Iodine brine drinking cure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iodine-balneotherapeutic programme
Number of subjects: 0
Study: 7038858

Group type: EXPERIMENTAL
Intervention: sulfinpyrazone (S)
Number of subjects: 186

Group type: COMPARATOR
Intervention: placebo (P)
Number of subjects: 186
Study: 31276165

Group type: EXPERIMENTAL
Intervention: Metronidazole (MET)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Metronidazole plus azithromycin (MET+AZ)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Pre-antibiotic microbiota profiles
Number of subjects: 67
Study: 28292299

Group type: EXPERIMENTAL
Intervention: Traditional training (classroom); n=16 CHAs in 8 churches
Number of subjects: 375

Group type: COMPARATOR
Intervention: Technology training (web-based); n=14 CHAs in 7 churches
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Traditional and Technology groups
Number of subjects: 375
Study: 27559855

Group type: EXPERIMENTAL
Intervention: Ginger group (GG) - 500 mg ginger powder daily for 3 months
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo group (PG) - 500 mg starch daily for 3 months
Number of subjects: 120
Study: 24709512

Group type: EXPERIMENTAL
Intervention: DBM with rhBMP-2 (0.05 mg/mL)
Number of subjects: 69

Group type: COMPARATOR
Intervention: DBM alone
Number of subjects: 69
Study: 22983931

Group type: EXPERIMENTAL
Intervention: Perturbation training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Strength training only
Number of subjects: 40
Study: 22029664

Group type: EXPERIMENTAL
Intervention: Questionnaires answered in English
Number of subjects: 145

Group type: COMPARATOR
Intervention: Questionnaires answered in Spanish
Number of subjects: 145
Study: 16338740

Group type: EXPERIMENTAL
Intervention: Breast cancer risk counseling intervention
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 150
Study: 12841551

Group type: EXPERIMENTAL
Intervention: Infiltration with 80 ml of 0.125 % Bupivacaine containing 5 mg of Phenylephrine (G2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Infiltration with 80 ml of 0.9 % NaCl (G3)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Infiltration with Bupivacaine/Phenylephrine and 200 ml of normal saline containing 0.15 % of Lidocaine (G4)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (G1) with no local anaesthetics
Number of subjects: 80
Study: 10825764

Group type: EXPERIMENTAL
Intervention: FFRmyo measurement before PTCA in Group 1 (AMI patients)
Number of subjects: 28

Group type: COMPARATOR
Intervention: FFRmyo measurement before PTCA in Group 2 (non-AMI patients)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: QCA-determined percent diameter stenosis in Group 1 (AMI patients)
Number of subjects: 28
Study: 8877075

Group type: EXPERIMENTAL
Intervention: Lisinopril, 20 mg/day by mouth
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (baseline conditions)
Number of subjects: 10
Study: 1498583

Group type: EXPERIMENTAL
Intervention: Alprazolam 1.0 mg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Buspirone 5 mg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Buspirone 10 mg
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 6337171

Group type: EXPERIMENTAL
Intervention: Disulfiram with riboflavin marker
Number of subjects: 124

Group type: COMPARATOR
Intervention: Riboflavin alone
Number of subjects: 124
Study: 31146701

Group type: EXPERIMENTAL
Intervention: Prediction score for acute kidney injury (AKI) based on risk factors including hypertension history, heart rate > 100 bpm on admission, peak serum troponin I ≥ 100 μg/L, time from admission to coronary reperfusion > 120 min, Killip classification ≥ class 3 on admission, maximum dosage of intravenous furosemide ≥ 60 mg/d, shock during hospitalization, and baseline estimated glomerular filtration rate (eGFR) < 90 ml/min·1.73 m2.
Number of subjects: 6014
Study: 29649669

Group type: EXPERIMENTAL
Intervention: 360-degree VR video
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 360-degree VR video + face to face teaching
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2D video teaching
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2D video teaching + face to face teaching
Number of subjects: 40
Study: 26251312

Group type: EXPERIMENTAL
Intervention: OTC medication (containing cetylpyridinium chloride, dipotassium glycyrrhizate, and allantoin) applied twice a day for 12 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: OTC medication
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 61
Study: 24521036

Group type: EXPERIMENTAL
Intervention: Penn Alcohol-Craving Scale (PCS)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Desires for Drug Questionnaire (DDQ) desire and intention scores
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Desires for Drug Questionnaire (DDQ) negative reinforcement scores
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Desires for Drug Questionnaire (DDQ) control scores
Number of subjects: 147